Product Images Dsuvia

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 11 images provide visual information about the product associated with Dsuvia NDC 61621-430 by Acelrx Pharmaceuticals, Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

sufentanil-figure-01 - sufentanil figure 01

sufentanil-figure-01 - sufentanil figure 01

This text provides instructions on how to administer medication from a pouch containing a single blue-colored tablet in a clear plastic SDA (sufentanil sublingual tablet) and an oxygen absorber packet. The user is instructed to tear open the notched pouch, remove the SDA from the pouch, and discard the oxygen absorber packet. Figure 1 shows a depiction of the content in the pouch.*

sufentanil-figure-02 - sufentanil figure 02

sufentanil-figure-02 - sufentanil figure 02

This text provides instructions for removing a white lock from a green pusher, as illustrated in Figure 2. After removing the lock, the user should discard it and take care not to accidentally eject the tablet. The text also cautions against touching the green pusher before administering the tablet to the patient. Overall, this text seems to be part of a set of instructions for administering medication.*

sufentanil-figure-03 - sufentanil figure 03

sufentanil-figure-03 - sufentanil figure 03

This text provides a step-by-step guide for administering medication using a sublingual drug applicator (SDA). The instructions include asking the patient to touch their tongue to the roof of their mouth, resting the SDA on the patient's lower teeth or lips, placing the SDA tip under the tongue, depressing the pusher to deliver the tablet to the sublingual space, visually confirming tablet placement, and discarding the used SDA in biohazard waste after administration. The text also includes figures to illustrate SDA placement for administration and tablet placement in the sublingual space.*

sufentanil-figure-04 - sufentanil figure 04

sufentanil-figure-04 - sufentanil figure 04

The text describes a graph that shows plasma concentration (measured in pg/mL) over time (up to 36 hours) after administering DSUVIA at a single dose of 30 mcg or multiple doses, represented by mean values and standard deviations.*

sufentanil-figure-05 - sufentanil figure 05

sufentanil-figure-05 - sufentanil figure 05

This text appears to be a graph showing the LS mean (SEM) for PID, with DSUVIA 30 mcg and placebo as the variables along the x-axis (represented at the bottom by time in hours) and the y-axis representing the values of LS mean. However, without a visual aid, it is difficult to fully assess the data shown.*

sufentanil-figure-06 - sufentanil figure 06

sufentanil-figure-06 - sufentanil figure 06

sufentanil-figure-07 - sufentanil figure 07

sufentanil-figure-07 - sufentanil figure 07

sufentanil-figure-08 - sufentanil figure 08

sufentanil-figure-08 - sufentanil figure 08

sufentanil-figure-09 - sufentanil figure 09

sufentanil-figure-09 - sufentanil figure 09

sufentanil-figure-10.jpg - sufentanil figure 10

sufentanil-figure-10.jpg - sufentanil figure 10

Inactive ingredients in a medication include mannitol, dicalcium phosphate anhydrous, hydroxypropyl methylcellulose, croscarmeliose sodium, FDEC Blue #2, stearic acid, and magnesium stearate. The product is made by AcelRx Pharmaceuticals, Inc. and more information can be found on the package insert or by visiting www.dsuvia.com/video. If there are any questions, contact 1-855.925-8476. The additional information has not been approved by the FDA.*

sufentanil-figure-11 - sufentanil figure 11

sufentanil-figure-11 - sufentanil figure 11

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.